T1	Premise 1025 1234	Relative to women continuing tamoxifen, women switching to anastrozole experienced a decrease of 53% (95% CI, 41%-63%) in double endometrial thickness and a decrease of 51% (95% CI, 39%-60%) in uterine volume.
T2	Premise 1235 1412	Vaginal dryness (b = 0.064; 95% CI, 0.016-0.112) and sexual problems (b = 0.054; 95% CI, 0.007-0.102) increased in women taking anastrozole compared with women taking tamoxifen.
T3	Premise 1413 1516	Treatment arms did not differ regarding withdrawal rate and the experience of (serious) adverse events.
T4	Claim 1587 1710	Switching to anastrozole strongly decreased the endometrial thickness and uterine volume but increased sexual disturbances.
T6	MajorClaim 1711 1787	Safe and effective interventions are needed to alleviate sexual dysfunction.
R1	Support Arg1:T2 Arg2:T4	
R2	Support Arg1:T1 Arg2:T4	
